Efficacy data from the phase III trial
Efficacy variable . | Randomized and treated patients . | . | Fully supplemented patients . | . | ||
---|---|---|---|---|---|---|
. | Pemetrexed + cisplatin (n = 226) . | Cisplatin (n = 222) . | Pemetrexed + cisplatin (n = 168) . | Cisplatin (n = 163) . | ||
Median overall survival, mo (95% confidence interval) | 12.1 (10.0-14.4) | 9.3 (7.8-10.7) | 13.3 (11.4-14.9) | 10.0 (8.4-11.9) | ||
Hazard ratio (95% confidence interval) | 0.77 (0.61-0.96) | 0.76 (0.57-1.0) | ||||
P (log-rank)* | 0.021 | 0.051 | ||||
% Alive | 35.8 | 28.4 | 43.5 | 36.8 |
Efficacy variable . | Randomized and treated patients . | . | Fully supplemented patients . | . | ||
---|---|---|---|---|---|---|
. | Pemetrexed + cisplatin (n = 226) . | Cisplatin (n = 222) . | Pemetrexed + cisplatin (n = 168) . | Cisplatin (n = 163) . | ||
Median overall survival, mo (95% confidence interval) | 12.1 (10.0-14.4) | 9.3 (7.8-10.7) | 13.3 (11.4-14.9) | 10.0 (8.4-11.9) | ||
Hazard ratio (95% confidence interval) | 0.77 (0.61-0.96) | 0.76 (0.57-1.0) | ||||
P (log-rank)* | 0.021 | 0.051 | ||||
% Alive | 35.8 | 28.4 | 43.5 | 36.8 |
P is based on the two-sided log-rank test.